Interleukin-17 (IL-17)

Author: V. Dimov, M.D., Allergist/Immunologist and Assistant Professor at University of Chicago
Reviewer: S. Randhawa, M.D., Allergist/Immunologist and Assistant Professor at NSU

IL-17 is actually not one cytokine but a family of 6 related cytokines - promote tissue damage in autoimmune diseases and play a role in defense against bacterial infections.

Differentiation and maintenance of IL-17-producing T cell subset are dependent on TGF-β, IL-23, IL-6.

There was a theme issue of JACI on IL-17 and Th17 cells (PDF).

TH17 cells produce IL-17, IL-6, TNF, and IL-22. TH17 cells are important for neutrophil recruitment and they contribute to autoimmune disorders.

T(H)17 cells are the newest member of the T(H) cell family and are characterized by their ability to produce cytokines such as:

- IL-17
- IL-17F
- IL-22
- CCL20

T(H)17 cells are also associated with the development of:

- allergic contact dermatitis
- atopic dermatitis
- asthma


T helper cells (click to enlarge the image).

Autosomal dominant hyper-IgE syndrome, a rare primary immunodeficiency disorder, is caused by mutations of signal transducer and activator of transcription 3 (STAT3), preventing T(H)17 lineage differentiation and increasing susceptibility to Staphylococcus and Candida species infections.

Anti-IL-17 Receptor Antibody Brodalumab Helps Patients with Psoriasis - NEJM, 2012. Anti–Interleukin-17 Monoclonal Antibody Ixekizumab Improves Chronic Plaque Psoriasis - NEJM, 2012.

Which cytokines promote neutrophil tissue inflammation?

(A) IL-2
(B) IL-5
(C) IL-8
(D) IL-10
(E) IL-17

Answers: IL-8 and IL-17.

References

Development and function of TH17 cells in health and disease. Louten J, Boniface K, de Waal Malefyt R. J Allergy Clin Immunol. 2009 May;123(5):1004-11.
Development and function of TH17 cells in health and disease. Louten J, Boniface K, de Waal Malefyt R. J Allergy Clin Immunol. 2009 May;123(5):1004-11.
Sarcoidosis is a Th1/Th17 multisystem disorder, Thorax 2011.
Anti-IL-17 Receptor Antibody Brodalumab Helps Patients with Psoriasis - NEJM, 2012.
Anti–Interleukin-17 Monoclonal Antibody Ixekizumab Improves Chronic Plaque Psoriasis - NEJM, 2012.

Published: 04/09/2010
Updated: 03/09/2012

No comments: